Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial
In DISCOVER, a multinational, randomised controlled trial, emtricitabine and tenofovir alafenamide compared with emtricitabine and tenofovir disoproxil fumarate showed non-inferior efficacy for HIV prevention and improved bone mineral density and renal safety biomarkers at week 48. We report outcome...
Uloženo v:
| Vydáno v: | The lancet HIV Ročník 8; číslo 7; s. e397 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Netherlands
01.07.2021
|
| Témata: | |
| ISSN: | 2352-3018, 2352-3018 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | In DISCOVER, a multinational, randomised controlled trial, emtricitabine and tenofovir alafenamide compared with emtricitabine and tenofovir disoproxil fumarate showed non-inferior efficacy for HIV prevention and improved bone mineral density and renal safety biomarkers at week 48. We report outcomes analysed after all participants had completed 96 weeks of follow-up.
This study is an ongoing, randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial done at 94 community, public health, and hospital-associated clinics located in Europe and North America. Adult cisgender men and transgender women who have sex with men, both with a high risk of acquiring HIV as determined by self-reported sexual behaviour or recent sexually transmitted infections, were randomly assigned (1:1) to receive either emtricitabine and tenofovir alafenamide (200/25 mg) tablets daily, with matched placebo tablets (emtricitabine and tenofovir alafenamide group), or emtricitabine and tenofovir disoproxil fumarate (200/300 mg) tablets daily, with matched placebo tablets (emtricitabine and tenofovir disoproxil fumarate group). The primary efficacy outcome was incident HIV infection. Incidence of HIV-1 infection per 100 person-years was assessed when the last participant had completed 96 weeks of follow-up. This trial is registered with ClinicalTrials.gov, number NCT02842086.
Between Sept 13, 2016, and June 30, 2017, 5387 participants were randomly assigned to receive emtricitabine and tenofovir alafenamide (n=2694) or emtricitabine and tenofovir disoproxil fumarate (n=2693), contributing 10 081 person-years of follow-up. At 96 weeks of follow-up, there were eight HIV infections in participants who had received emtricitabine and tenofovir alafenamide (0·16 infections per 100 person-years [95% CI 0·07-0·31]) and 15 in participants who had received emtricitabine and tenofovir disoproxil fumarate (0·30 infections per 100 person-years [0·17-0·49]). Emtricitabine and tenofovir alafenamide maintained its non-inferiority to emtricitabine and tenofovir disoproxil fumarate for HIV prevention (IRR 0·54 [95% CI 0·23-1·26]). Approximately 78-82% of participants reported taking study medication more than 95% of the time across all study visits. Rates of sexually transmitted infections remained high and similar across groups (21 cases per 100 person-years for rectal gonorrhoea and 28 cases per 100 person-years for rectal chlamydia). Emtricitabine and tenofovir alafenamide continued to show superiority over emtricitabine and tenofovir disoproxil fumarate in all but one of the six prespecified bone mineral density and renal biomarkers. There was more weight gain among participants who had received emtricitabine and tenofovir alafenamide (median weight gain 1·7 kg vs 0·5 kg, p<0·0001).
Emtricitabine and tenofovir alafenamide is safe and effective for longer-term pre-exposure prophylaxis in cisgender men and transgender women who have sex with men.
Gilead Sciences. |
|---|---|
| AbstractList | In DISCOVER, a multinational, randomised controlled trial, emtricitabine and tenofovir alafenamide compared with emtricitabine and tenofovir disoproxil fumarate showed non-inferior efficacy for HIV prevention and improved bone mineral density and renal safety biomarkers at week 48. We report outcomes analysed after all participants had completed 96 weeks of follow-up.BACKGROUNDIn DISCOVER, a multinational, randomised controlled trial, emtricitabine and tenofovir alafenamide compared with emtricitabine and tenofovir disoproxil fumarate showed non-inferior efficacy for HIV prevention and improved bone mineral density and renal safety biomarkers at week 48. We report outcomes analysed after all participants had completed 96 weeks of follow-up.This study is an ongoing, randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial done at 94 community, public health, and hospital-associated clinics located in Europe and North America. Adult cisgender men and transgender women who have sex with men, both with a high risk of acquiring HIV as determined by self-reported sexual behaviour or recent sexually transmitted infections, were randomly assigned (1:1) to receive either emtricitabine and tenofovir alafenamide (200/25 mg) tablets daily, with matched placebo tablets (emtricitabine and tenofovir alafenamide group), or emtricitabine and tenofovir disoproxil fumarate (200/300 mg) tablets daily, with matched placebo tablets (emtricitabine and tenofovir disoproxil fumarate group). The primary efficacy outcome was incident HIV infection. Incidence of HIV-1 infection per 100 person-years was assessed when the last participant had completed 96 weeks of follow-up. This trial is registered with ClinicalTrials.gov, number NCT02842086.METHODSThis study is an ongoing, randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial done at 94 community, public health, and hospital-associated clinics located in Europe and North America. Adult cisgender men and transgender women who have sex with men, both with a high risk of acquiring HIV as determined by self-reported sexual behaviour or recent sexually transmitted infections, were randomly assigned (1:1) to receive either emtricitabine and tenofovir alafenamide (200/25 mg) tablets daily, with matched placebo tablets (emtricitabine and tenofovir alafenamide group), or emtricitabine and tenofovir disoproxil fumarate (200/300 mg) tablets daily, with matched placebo tablets (emtricitabine and tenofovir disoproxil fumarate group). The primary efficacy outcome was incident HIV infection. Incidence of HIV-1 infection per 100 person-years was assessed when the last participant had completed 96 weeks of follow-up. This trial is registered with ClinicalTrials.gov, number NCT02842086.Between Sept 13, 2016, and June 30, 2017, 5387 participants were randomly assigned to receive emtricitabine and tenofovir alafenamide (n=2694) or emtricitabine and tenofovir disoproxil fumarate (n=2693), contributing 10 081 person-years of follow-up. At 96 weeks of follow-up, there were eight HIV infections in participants who had received emtricitabine and tenofovir alafenamide (0·16 infections per 100 person-years [95% CI 0·07-0·31]) and 15 in participants who had received emtricitabine and tenofovir disoproxil fumarate (0·30 infections per 100 person-years [0·17-0·49]). Emtricitabine and tenofovir alafenamide maintained its non-inferiority to emtricitabine and tenofovir disoproxil fumarate for HIV prevention (IRR 0·54 [95% CI 0·23-1·26]). Approximately 78-82% of participants reported taking study medication more than 95% of the time across all study visits. Rates of sexually transmitted infections remained high and similar across groups (21 cases per 100 person-years for rectal gonorrhoea and 28 cases per 100 person-years for rectal chlamydia). Emtricitabine and tenofovir alafenamide continued to show superiority over emtricitabine and tenofovir disoproxil fumarate in all but one of the six prespecified bone mineral density and renal biomarkers. There was more weight gain among participants who had received emtricitabine and tenofovir alafenamide (median weight gain 1·7 kg vs 0·5 kg, p<0·0001).FINDINGSBetween Sept 13, 2016, and June 30, 2017, 5387 participants were randomly assigned to receive emtricitabine and tenofovir alafenamide (n=2694) or emtricitabine and tenofovir disoproxil fumarate (n=2693), contributing 10 081 person-years of follow-up. At 96 weeks of follow-up, there were eight HIV infections in participants who had received emtricitabine and tenofovir alafenamide (0·16 infections per 100 person-years [95% CI 0·07-0·31]) and 15 in participants who had received emtricitabine and tenofovir disoproxil fumarate (0·30 infections per 100 person-years [0·17-0·49]). Emtricitabine and tenofovir alafenamide maintained its non-inferiority to emtricitabine and tenofovir disoproxil fumarate for HIV prevention (IRR 0·54 [95% CI 0·23-1·26]). Approximately 78-82% of participants reported taking study medication more than 95% of the time across all study visits. Rates of sexually transmitted infections remained high and similar across groups (21 cases per 100 person-years for rectal gonorrhoea and 28 cases per 100 person-years for rectal chlamydia). Emtricitabine and tenofovir alafenamide continued to show superiority over emtricitabine and tenofovir disoproxil fumarate in all but one of the six prespecified bone mineral density and renal biomarkers. There was more weight gain among participants who had received emtricitabine and tenofovir alafenamide (median weight gain 1·7 kg vs 0·5 kg, p<0·0001).Emtricitabine and tenofovir alafenamide is safe and effective for longer-term pre-exposure prophylaxis in cisgender men and transgender women who have sex with men.INTERPRETATIONEmtricitabine and tenofovir alafenamide is safe and effective for longer-term pre-exposure prophylaxis in cisgender men and transgender women who have sex with men.Gilead Sciences.FUNDINGGilead Sciences. In DISCOVER, a multinational, randomised controlled trial, emtricitabine and tenofovir alafenamide compared with emtricitabine and tenofovir disoproxil fumarate showed non-inferior efficacy for HIV prevention and improved bone mineral density and renal safety biomarkers at week 48. We report outcomes analysed after all participants had completed 96 weeks of follow-up. This study is an ongoing, randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial done at 94 community, public health, and hospital-associated clinics located in Europe and North America. Adult cisgender men and transgender women who have sex with men, both with a high risk of acquiring HIV as determined by self-reported sexual behaviour or recent sexually transmitted infections, were randomly assigned (1:1) to receive either emtricitabine and tenofovir alafenamide (200/25 mg) tablets daily, with matched placebo tablets (emtricitabine and tenofovir alafenamide group), or emtricitabine and tenofovir disoproxil fumarate (200/300 mg) tablets daily, with matched placebo tablets (emtricitabine and tenofovir disoproxil fumarate group). The primary efficacy outcome was incident HIV infection. Incidence of HIV-1 infection per 100 person-years was assessed when the last participant had completed 96 weeks of follow-up. This trial is registered with ClinicalTrials.gov, number NCT02842086. Between Sept 13, 2016, and June 30, 2017, 5387 participants were randomly assigned to receive emtricitabine and tenofovir alafenamide (n=2694) or emtricitabine and tenofovir disoproxil fumarate (n=2693), contributing 10 081 person-years of follow-up. At 96 weeks of follow-up, there were eight HIV infections in participants who had received emtricitabine and tenofovir alafenamide (0·16 infections per 100 person-years [95% CI 0·07-0·31]) and 15 in participants who had received emtricitabine and tenofovir disoproxil fumarate (0·30 infections per 100 person-years [0·17-0·49]). Emtricitabine and tenofovir alafenamide maintained its non-inferiority to emtricitabine and tenofovir disoproxil fumarate for HIV prevention (IRR 0·54 [95% CI 0·23-1·26]). Approximately 78-82% of participants reported taking study medication more than 95% of the time across all study visits. Rates of sexually transmitted infections remained high and similar across groups (21 cases per 100 person-years for rectal gonorrhoea and 28 cases per 100 person-years for rectal chlamydia). Emtricitabine and tenofovir alafenamide continued to show superiority over emtricitabine and tenofovir disoproxil fumarate in all but one of the six prespecified bone mineral density and renal biomarkers. There was more weight gain among participants who had received emtricitabine and tenofovir alafenamide (median weight gain 1·7 kg vs 0·5 kg, p<0·0001). Emtricitabine and tenofovir alafenamide is safe and effective for longer-term pre-exposure prophylaxis in cisgender men and transgender women who have sex with men. Gilead Sciences. |
| Author | Ogbuagu, Onyema Salazar, Laura C Spinner, Christoph D Kronborg, Gitte Ruane, Peter J Gilson, Richard Brainard, Diana M Shao, Yongwu Asmuth, David M Brunetta, Jason M Wohl, David Henry, Keith Carter, Christoph Cox, Stephanie Whitlock, Gary Podzamczer, Daniel Kintu, Alexander Das, Moupali Baeten, Jared M Ebrahimi, Ramin |
| Author_xml | – sequence: 1 givenname: Onyema surname: Ogbuagu fullname: Ogbuagu, Onyema email: onyema.ogbuagu@yale.edu organization: School of Medicine, Yale University, New Haven, CT, USA. Electronic address: onyema.ogbuagu@yale.edu – sequence: 2 givenname: Peter J surname: Ruane fullname: Ruane, Peter J organization: Ruane Clinical Research, Los Angeles, CA, USA – sequence: 3 givenname: Daniel surname: Podzamczer fullname: Podzamczer, Daniel organization: HIV and STI Unit, Infectious Disease Department, Hospital Universitario de Bellvitge, Barcelona, Spain – sequence: 4 givenname: Laura C surname: Salazar fullname: Salazar, Laura C organization: Hoag Medical Group, Newport Beach, CA, USA – sequence: 5 givenname: Keith surname: Henry fullname: Henry, Keith organization: Hennepin Healthcare Research Institute, Minneapolis, MN, USA – sequence: 6 givenname: David M surname: Asmuth fullname: Asmuth, David M organization: School of Medicine, University of California Davis, Davis, CA, USA – sequence: 7 givenname: David surname: Wohl fullname: Wohl, David organization: Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA – sequence: 8 givenname: Richard surname: Gilson fullname: Gilson, Richard organization: Centre for Clinical Research in Infection and Sexual Health, University College London, London, UK – sequence: 9 givenname: Yongwu surname: Shao fullname: Shao, Yongwu organization: Departments of Biometrics, Virology, and Clinical Research, Gilead Sciences, Foster City, CA, USA – sequence: 10 givenname: Ramin surname: Ebrahimi fullname: Ebrahimi, Ramin organization: Departments of Biometrics, Virology, and Clinical Research, Gilead Sciences, Foster City, CA, USA – sequence: 11 givenname: Stephanie surname: Cox fullname: Cox, Stephanie organization: Departments of Biometrics, Virology, and Clinical Research, Gilead Sciences, Foster City, CA, USA – sequence: 12 givenname: Alexander surname: Kintu fullname: Kintu, Alexander organization: Departments of Biometrics, Virology, and Clinical Research, Gilead Sciences, Foster City, CA, USA – sequence: 13 givenname: Christoph surname: Carter fullname: Carter, Christoph organization: Departments of Biometrics, Virology, and Clinical Research, Gilead Sciences, Foster City, CA, USA – sequence: 14 givenname: Moupali surname: Das fullname: Das, Moupali organization: Departments of Biometrics, Virology, and Clinical Research, Gilead Sciences, Foster City, CA, USA – sequence: 15 givenname: Jared M surname: Baeten fullname: Baeten, Jared M organization: Departments of Biometrics, Virology, and Clinical Research, Gilead Sciences, Foster City, CA, USA – sequence: 16 givenname: Diana M surname: Brainard fullname: Brainard, Diana M organization: Departments of Biometrics, Virology, and Clinical Research, Gilead Sciences, Foster City, CA, USA – sequence: 17 givenname: Gary surname: Whitlock fullname: Whitlock, Gary organization: Chelsea and Westminster Hospital NHS Foundation Trust, London, UK – sequence: 18 givenname: Jason M surname: Brunetta fullname: Brunetta, Jason M organization: Maple Leaf Medical Clinic, Toronto, ON, Canada – sequence: 19 givenname: Gitte surname: Kronborg fullname: Kronborg, Gitte organization: Department of Infectious Diseases, University of Copenhagen, Hvidovre Hospital, Denmark – sequence: 20 givenname: Christoph D surname: Spinner fullname: Spinner, Christoph D organization: Technical University of Munich, Munich, Germany |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34197772$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kcluFDEQhi0URELII4DqGCQMXnobblEEJNJIHFiuIy9lYnDbje0OM6_NE2AgIE6cavvqVy0PyVFMEQl5zNlzzvjw4p2QvaCS8elc8KeMsZFTdo-c_E0f_eMfk7NSPjeI993Ud-IBOZYd34zjKE7I922Kn2jFPENRDusBVLSAznmjzAGSA5xr9sZXpX3EX9WKMbl06zOo0Hqimr1FuC3_Ra0vaclp7wO4dVZZVQSXMlxdf6QclowU90sqa8YWpOXmENTel5fwDfELbAbIWNZQC7icZlCQm3qafUH7DGxadUCqg48tWoIyqBM1KdacQvhJLDeqIEho46nwiNx3KhQ8u7On5MPrV-8vr-j27Zvry4stNZ0cGFVCdGzi0ySs1CNaZxkyrvU4jdIK6VAbOwk-9KM0dthYoRohkenOup6hFqfk_Ldu2-friqXu2rwGQ1AR01p2or2j47wfWEOf3KGrntHuluzbiQ67P38SPwCpwp5B |
| CitedBy_id | crossref_primary_10_1001_jama_2023_14461 crossref_primary_10_3390_antiox13050518 crossref_primary_10_1001_jamanetworkopen_2023_30195 crossref_primary_10_1016_j_ebiom_2022_104338 crossref_primary_10_1097_EBP_0000000000001701 crossref_primary_10_1016_j_idc_2024_04_005 crossref_primary_10_1080_17512433_2023_2251387 crossref_primary_10_1111_hiv_70043 crossref_primary_10_2196_57348 crossref_primary_10_1080_17512433_2024_2350968 crossref_primary_10_1016_j_ijbiomac_2022_08_211 crossref_primary_10_1097_QAI_0000000000003091 crossref_primary_10_1186_s12879_025_11476_3 crossref_primary_10_1093_cid_ciae191 crossref_primary_10_1007_s10461_025_04786_9 crossref_primary_10_1590_0102_311xen089522 crossref_primary_10_1097_QAD_0000000000003950 crossref_primary_10_1186_s12889_025_22499_5 crossref_primary_10_1097_JNC_0000000000000521 crossref_primary_10_1097_QAD_0000000000003077 crossref_primary_10_1016_S0140_6736_23_01381_8 crossref_primary_10_1001_jama_2022_22246 crossref_primary_10_1002_cpt_2845 crossref_primary_10_1002_jac5_1843 crossref_primary_10_1177_09564624241272940 crossref_primary_10_1093_cid_ciae143 crossref_primary_10_1007_s11904_024_00704_1 crossref_primary_10_1016_j_bioorg_2024_107150 crossref_primary_10_1111_apt_17793 crossref_primary_10_1093_jac_dkac336 crossref_primary_10_1001_jamanetworkopen_2023_32968 crossref_primary_10_1016_S2352_3018_22_00133_3 crossref_primary_10_3390_tropicalmed10030075 crossref_primary_10_1136_bmjopen_2020_048478 crossref_primary_10_1111_hiv_13432 crossref_primary_10_1097_QAD_0000000000004148 crossref_primary_10_1155_2022_3913439 crossref_primary_10_1093_cid_ciaf221 crossref_primary_10_1093_infdis_jiad507 crossref_primary_10_1093_ofid_ofad695 crossref_primary_10_1016_S2352_3018_23_00080_2 crossref_primary_10_1001_jama_2023_9865 crossref_primary_10_1371_journal_pone_0267780 crossref_primary_10_1155_cjid_9340622 crossref_primary_10_1097_MOP_0000000000001357 crossref_primary_10_3390_pharmaceutics14061285 crossref_primary_10_3390_ijerph20032582 crossref_primary_10_1097_QAD_0000000000003455 crossref_primary_10_1007_s10508_025_03195_2 crossref_primary_10_1016_j_ijregi_2023_01_004 crossref_primary_10_1016_S2352_3018_25_00079_7 crossref_primary_10_1097_QAD_0000000000004232 crossref_primary_10_1093_cid_ciad433 crossref_primary_10_1093_jpids_piaf062 crossref_primary_10_1016_S2352_3018_24_00130_9 crossref_primary_10_1080_26895269_2024_2402743 crossref_primary_10_1002_phar_2796 crossref_primary_10_3389_fphar_2023_1294966 crossref_primary_10_1097_COH_0000000000000747 crossref_primary_10_1097_COH_0000000000000746 crossref_primary_10_3390_pharmaceutics13122193 |
| ContentType | Journal Article |
| Contributor | Mayer, Kenneth Benson, Paul Hodge, Jr, Theo Voskuhl, Gene Berhe, Mezgebe Lucasti, Christopher Mills, Anthony Leen, Clifford Martorell, Claudia Tremblay, Cecile Larsen, Olav Ditlevsen de Wet, Joseph Ogbuagu, Onyema Creticos, Catherine Phoenix, John Kronborg, Gitte Shalit, Peter Gerstoft, Jan Szabo, Jason Gilson, Richard Grossberg, Robert Mounzer, Karam Gallant, Joel Podzamczer, Daniel Salazar, Laura Bergin, Colm Jessen, Heiko Rashbaum, Bruce Stephens, Jeffrey Flamm, Jason Mannheimer, Sharon Knecht, Gabriele Hare, Charles LaMarca, Anthony Markowitz, Martin Apea, Vanessa Grant, Robert Antinori, Andrea Larsen, Carsten Schade Campbell, Thomas Henry, William Kegg, Stephen Coll, Josep Donovan, Taylor Nwokolo, Nneka Molina, Jean-Michel Daar, Eric Hengel, Richard Ramgopal, Moti Doblecki-Lewis, Susanne Brar, Indira Dosekun, Olamide Halperin, Jason Morris, Sheldon Prins, Maria Scott, Mia Cruickshank, Frederick Hurt, Christopher Ruane, Peter Cespedes, Michelle Hosek, Sybil Wohl, David Osiyemi, Olayemi Hardy, W David Lazzarin, Adriano Sobieszczyk, Magdalena Reeve |
| Contributor_xml | – sequence: 1 givenname: Andrea surname: Antinori fullname: Antinori, Andrea – sequence: 2 givenname: Vanessa surname: Apea fullname: Apea, Vanessa – sequence: 3 givenname: David surname: Asmuth fullname: Asmuth, David – sequence: 4 givenname: Ann surname: Avery fullname: Avery, Ann – sequence: 5 givenname: Paul surname: Benson fullname: Benson, Paul – sequence: 6 givenname: Colm surname: Bergin fullname: Bergin, Colm – sequence: 7 givenname: Mezgebe surname: Berhe fullname: Berhe, Mezgebe – sequence: 8 givenname: Indira surname: Brar fullname: Brar, Indira – sequence: 9 givenname: Cynthia surname: Brinson fullname: Brinson, Cynthia – sequence: 10 givenname: Jason surname: Brunetta fullname: Brunetta, Jason – sequence: 11 givenname: Jeffrey surname: Burack fullname: Burack, Jeffrey – sequence: 12 givenname: Thomas surname: Campbell fullname: Campbell, Thomas – sequence: 13 givenname: Michelle surname: Cespedes fullname: Cespedes, Michelle – sequence: 14 givenname: Amanda surname: Clarke fullname: Clarke, Amanda – sequence: 15 givenname: Megan surname: Coleman fullname: Coleman, Megan – sequence: 16 givenname: Josep surname: Coll fullname: Coll, Josep – sequence: 17 givenname: Manuel surname: Crespo Casal fullname: Crespo Casal, Manuel – sequence: 18 givenname: Catherine surname: Creticos fullname: Creticos, Catherine – sequence: 19 givenname: Gordon surname: Crofoot fullname: Crofoot, Gordon – sequence: 20 givenname: Frederick surname: Cruickshank fullname: Cruickshank, Frederick – sequence: 21 givenname: Eric surname: Cua fullname: Cua, Eric – sequence: 22 givenname: Eric surname: Daar fullname: Daar, Eric – sequence: 23 givenname: Joseph surname: de Wet fullname: de Wet, Joseph – sequence: 24 givenname: Edwin surname: DeJesus fullname: DeJesus, Edwin – sequence: 25 givenname: Jorge surname: Del Romero Guerrero fullname: Del Romero Guerrero, Jorge – sequence: 26 givenname: William surname: Dinges fullname: Dinges, William – sequence: 27 givenname: Susanne surname: Doblecki-Lewis fullname: Doblecki-Lewis, Susanne – sequence: 28 givenname: Taylor surname: Donovan fullname: Donovan, Taylor – sequence: 29 givenname: Olamide surname: Dosekun fullname: Dosekun, Olamide – sequence: 30 givenname: Jason surname: Flamm fullname: Flamm, Jason – sequence: 31 givenname: Joel surname: Gallant fullname: Gallant, Joel – sequence: 32 givenname: Jan surname: Gerstoft fullname: Gerstoft, Jan – sequence: 33 givenname: Richard surname: Gilson fullname: Gilson, Richard – sequence: 34 givenname: Jay surname: Gladstein fullname: Gladstein, Jay – sequence: 35 givenname: Robert surname: Grant fullname: Grant, Robert – sequence: 36 givenname: Robert surname: Grossberg fullname: Grossberg, Robert – sequence: 37 givenname: Bernhard surname: Haas fullname: Haas, Bernhard – sequence: 38 givenname: Jason surname: Halperin fullname: Halperin, Jason – sequence: 39 givenname: W David surname: Hardy fullname: Hardy, W David – sequence: 40 givenname: Charles surname: Hare fullname: Hare, Charles – sequence: 41 givenname: Shawn surname: Hassler fullname: Hassler, Shawn – sequence: 42 givenname: Richard surname: Hengel fullname: Hengel, Richard – sequence: 43 givenname: William surname: Henry fullname: Henry, William – sequence: 44 givenname: Theo surname: Hodge, Jr fullname: Hodge, Jr, Theo – sequence: 45 givenname: Sybil surname: Hosek fullname: Hosek, Sybil – sequence: 46 givenname: Christopher surname: Hurt fullname: Hurt, Christopher – sequence: 47 givenname: Michelle surname: Iandiorio fullname: Iandiorio, Michelle – sequence: 48 givenname: Heiko surname: Jessen fullname: Jessen, Heiko – sequence: 49 givenname: Stephen surname: Kegg fullname: Kegg, Stephen – sequence: 50 givenname: Gabriele surname: Knecht fullname: Knecht, Gabriele – sequence: 51 givenname: Gitte surname: Kronborg fullname: Kronborg, Gitte – sequence: 52 givenname: Ivanka surname: Krznaric fullname: Krznaric, Ivanka – sequence: 53 givenname: Anthony surname: LaMarca fullname: LaMarca, Anthony – sequence: 54 givenname: Carsten Schade surname: Larsen fullname: Larsen, Carsten Schade – sequence: 55 givenname: Olav Ditlevsen surname: Larsen fullname: Larsen, Olav Ditlevsen – sequence: 56 givenname: Adriano surname: Lazzarin fullname: Lazzarin, Adriano – sequence: 57 givenname: Clifford surname: Leen fullname: Leen, Clifford – sequence: 58 givenname: Christopher surname: Lucasti fullname: Lucasti, Christopher – sequence: 59 givenname: Patrick surname: Mallon fullname: Mallon, Patrick – sequence: 60 givenname: Sharon surname: Mannheimer fullname: Mannheimer, Sharon – sequence: 61 givenname: Martin surname: Markowitz fullname: Markowitz, Martin – sequence: 62 givenname: Claudia surname: Martorell fullname: Martorell, Claudia – sequence: 63 givenname: Kenneth surname: Mayer fullname: Mayer, Kenneth – sequence: 64 givenname: Anthony surname: Mills fullname: Mills, Anthony – sequence: 65 givenname: Jean-Michel surname: Molina fullname: Molina, Jean-Michel – sequence: 66 givenname: Sheldon surname: Morris fullname: Morris, Sheldon – sequence: 67 givenname: Karam surname: Mounzer fullname: Mounzer, Karam – sequence: 68 givenname: Nneka surname: Nwokolo fullname: Nwokolo, Nneka – sequence: 69 givenname: Onyema surname: Ogbuagu fullname: Ogbuagu, Onyema – sequence: 70 givenname: Olayemi surname: Osiyemi fullname: Osiyemi, Olayemi – sequence: 71 givenname: Andrew surname: Petroll fullname: Petroll, Andrew – sequence: 72 givenname: Patrick surname: Philibert fullname: Philibert, Patrick – sequence: 73 givenname: John surname: Phoenix fullname: Phoenix, John – sequence: 74 givenname: Gilles surname: Pialoux fullname: Pialoux, Gilles – sequence: 75 givenname: Daniel surname: Podzamczer fullname: Podzamczer, Daniel – sequence: 76 givenname: Frank surname: Post fullname: Post, Frank – sequence: 77 givenname: Maria surname: Prins fullname: Prins, Maria – sequence: 78 givenname: Moti surname: Ramgopal fullname: Ramgopal, Moti – sequence: 79 givenname: Bruce surname: Rashbaum fullname: Rashbaum, Bruce – sequence: 80 givenname: Iain surname: Reeves fullname: Reeves, Iain – sequence: 81 givenname: Gary surname: Richmond fullname: Richmond, Gary – sequence: 82 givenname: Armin surname: Rieger fullname: Rieger, Armin – sequence: 83 givenname: Peter surname: Ruane fullname: Ruane, Peter – sequence: 84 givenname: Laura surname: Salazar fullname: Salazar, Laura – sequence: 85 givenname: Anthony surname: Scarsella fullname: Scarsella, Anthony – sequence: 86 givenname: Gabriel surname: Schembri fullname: Schembri, Gabriel – sequence: 87 givenname: Mia surname: Scott fullname: Scott, Mia – sequence: 88 givenname: Peter surname: Shalit fullname: Shalit, Peter – sequence: 89 givenname: Gary surname: Sinclair fullname: Sinclair, Gary – sequence: 90 givenname: Magdalena surname: Sobieszczyk fullname: Sobieszczyk, Magdalena – sequence: 91 givenname: Christoph surname: Spinner fullname: Spinner, Christoph – sequence: 92 givenname: Jeffrey surname: Stephens fullname: Stephens, Jeffrey – sequence: 93 givenname: Jason surname: Szabo fullname: Szabo, Jason – sequence: 94 givenname: Stephen surname: Taylor fullname: Taylor, Stephen – sequence: 95 givenname: Melanie surname: Thompson fullname: Thompson, Melanie – sequence: 96 givenname: Cecile surname: Tremblay fullname: Tremblay, Cecile – sequence: 97 givenname: Benoit surname: Trottier fullname: Trottier, Benoit – sequence: 98 givenname: Gene surname: Voskuhl fullname: Voskuhl, Gene – sequence: 99 givenname: Barbara surname: Wade fullname: Wade, Barbara – sequence: 100 givenname: David surname: Wohl fullname: Wohl, David |
| Copyright | Copyright © 2021 Elsevier Ltd. All rights reserved. |
| Copyright_xml | – notice: Copyright © 2021 Elsevier Ltd. All rights reserved. |
| CorporateAuthor | DISCOVER study team |
| CorporateAuthor_xml | – name: DISCOVER study team |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/S2352-3018(21)00071-0 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2352-3018 |
| ExternalDocumentID | 34197772 |
| Genre | Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation | Gilead Sciences. |
| GrantInformation_xml | – fundername: NIAID NIH HHS grantid: P30 AI050410 |
| GroupedDBID | -RU .1- .FO 0R~ 1P~ 4.4 457 53G AAEDT AAEDW AALRI AAMRU AAQFI AAXUO ABJNI ACGFS ADBBV AENEX AFRHN AFTJW AITUG AJUYK ALMA_UNASSIGNED_HOLDINGS AMRAJ APXCP CGR CUY CVF EBS ECM EFKBS EIF EJD FDB HZ~ M41 NPM O9- OD- OO. ROL Z5R 7X8 |
| ID | FETCH-LOGICAL-c4360-a224081882d3b7edfd0e01bb7873d23febcd8216573cd69d2afd03e0b4df50eb2 |
| IEDL.DBID | 7X8 |
| ISSN | 2352-3018 |
| IngestDate | Sat Sep 27 17:19:15 EDT 2025 Mon Oct 06 01:41:16 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Language | English |
| License | Copyright © 2021 Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4360-a224081882d3b7edfd0e01bb7873d23febcd8216573cd69d2afd03e0b4df50eb2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://pure.amc.nl/en/publications/longterm-safety-and-efficacy-of-emtricitabine-and-tenofovir-alafenamide-vs-emtricitabine-and-tenofovir-disoproxil-fumarate-for-hiv1-preexposure-prophylaxis-week-96-results-from-a-randomised-doubleblind-placebocontrolled-phase-3-trial(f6eb88bf-36be-4e06-b072-12b0903e6368).html |
| PMID | 34197772 |
| PQID | 2548411560 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2548411560 pubmed_primary_34197772 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-07-01 |
| PublicationDateYYYYMMDD | 2021-07-01 |
| PublicationDate_xml | – month: 07 year: 2021 text: 2021-07-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | The lancet HIV |
| PublicationTitleAlternate | Lancet HIV |
| PublicationYear | 2021 |
| References | 34571044 - Lancet HIV. 2021 Dec;8(12):e734. doi: 10.1016/S2352-3018(21)00264-2. |
| References_xml | – reference: 34571044 - Lancet HIV. 2021 Dec;8(12):e734. doi: 10.1016/S2352-3018(21)00264-2. |
| SSID | ssj0001548542 |
| Score | 2.468532 |
| Snippet | In DISCOVER, a multinational, randomised controlled trial, emtricitabine and tenofovir alafenamide compared with emtricitabine and tenofovir disoproxil... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | e397 |
| SubjectTerms | Adenine - adverse effects Adenine - analogs & derivatives Adenine - therapeutic use Adult Aged Alanine - adverse effects Alanine - therapeutic use Anti-HIV Agents - adverse effects Anti-HIV Agents - therapeutic use Double-Blind Method Drug Therapy, Combination - adverse effects Emtricitabine - adverse effects Emtricitabine - therapeutic use Female Follow-Up Studies HIV Infections - prevention & control HIV Infections - virology HIV-1 - drug effects HIV-1 - physiology Humans Male Middle Aged Organophosphonates - adverse effects Organophosphonates - therapeutic use Pre-Exposure Prophylaxis Tenofovir - adverse effects Tenofovir - therapeutic use Treatment Outcome Young Adult |
| Title | Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/34197772 https://www.proquest.com/docview/2548411560 |
| Volume | 8 |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Li9RAEG7UVfDi-7G-KMGDgs120nm1FxFxWWEdFnwwt6E7Xa3BmB4nM-PO3_YXWJXJOidF8BJI0g0JVVR9Xf11fUI8UVgneV0ZmVfcVLtCJZ03RmrjDRYqEMoYLH1cTibVdGpOxoJbP9Iqz2LiEKh9rLlGfkALmSpL-Nzvy_l3yapRvLs6SmicF3uaoAxTuspptaux0Jx80M9JCWdI8uVqd4jn4P3vh0_T5NmQbKX6M9AcEs7h1f_91Gviygg14dXWN66Lc9jdEJe24pObm-Lncew-S47M0NuAyw3YzgNySwlbbyAGwG_cvr9ZWlo94_CWAHYMcd0swLY0h8XsPcK6_-tQJiwxW6ZpITChm9AtEFSGo7efZAJMQ8HTeeRKJd1EMntrT5v-BfxA_AqmgAX2q3bZA5-EAQuUXH0k70T_HHxcuRalI6xMdwO_zEU50u9bHjH_QmkaNAzqJLfEx8M3H14fyVEBQtaZLpS0DDgIUlSp165EH7xClThHUUb7VAd0ta_SpMhLXfvC-NTSCI3KZT7kCl16W1zoYod3BRShNDb3IWBRZInNLLkL6izzSalNUGFfPD4z5oz-gbdNbIdx1c925twXd7YeMZtvW4HMuBteSQuUe_8w-764nDIhZuD6PhB7geILPhQX6_Wy6RePBtel6-Tk3S_RWvye |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Long-term+safety+and+efficacy+of+emtricitabine+and+tenofovir+alafenamide+vs+emtricitabine+and+tenofovir+disoproxil+fumarate+for+HIV-1+pre-exposure+prophylaxis%3A+week+96+results+from+a+randomised%2C+double-blind%2C+placebo-controlled%2C+phase+3+trial&rft.jtitle=The+lancet+HIV&rft.au=Ogbuagu%2C+Onyema&rft.au=Ruane%2C+Peter+J&rft.au=Podzamczer%2C+Daniel&rft.au=Salazar%2C+Laura+C&rft.date=2021-07-01&rft.eissn=2352-3018&rft.volume=8&rft.issue=7&rft.spage=e397&rft_id=info:doi/10.1016%2FS2352-3018%2821%2900071-0&rft_id=info%3Apmid%2F34197772&rft_id=info%3Apmid%2F34197772&rft.externalDocID=34197772 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2352-3018&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2352-3018&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2352-3018&client=summon |